June 1, 2012 (Vol. 32, No. 11)
EMD Millipore promoted Andrew Bulpin, Ph.D., to head of global pharmaceutical chemicals solutions sales. Dr. Bulpin joined Millipore in 2006 as vp for the upstream processing business unit and assumed leadership of the services and solutions business in January 2012.
Pathway Genomics added Arne Astrup, M.D., Ph.D., Claude Bouchard, Ph.D., and Ken Fujioka, M.D., to its scientific advisory board…Jennerex elected Mitchell H. Gold, M.D., to its board of directors…Orgenesis appointed Guy Yachin and Yaron Adler to its board of directors and added G. Alexander Fleming, M.D., to its scientific advisory board.
Tom Pike is now CEO of Quintiles. Pike worked for 22 years at Accenture. There, he led the North America health andp roducts business areas, was the global COO for Accenture’s resources operating group, and has also served as its CSO.
Ultragenyx appointed Shalini Sharp as CFO and svp, finance…Michael Kaleko, M.D., Ph.D., joined Synthetic Biologics as scientific director…Taro Pharmaceutical Industries appointed Kalyanasundaram Subramanian (Kal Sundaram) as chairman of its board of directors…Response Genetics appointed Stephanie H. Astrow, Ph.D., as vp, R&D.
Rempex Pharmaceuticals appointed Jennifer Cayer as COO. Cayer was previously svp of commercial development at Conatus Pharmaceuticals, which she also co-founded. Prior to that, Cayer was vp, corporate development for Idun Pharmaceuticals.
Sorbent Therapeutics appointed Howard C. Dittrich, M.D., as CMO and Randall E. Woods as chairman of its board of directors…CombiMatrix named Richard Hockett, M.D., medical director and added Ronald J. Wapner, M.D., to its scientific advisory board…Vivus appointed Ernest Mario, Ph.D., to serve on its board of directors…Sanguine BioSciences added Timothy J. Triche, M.D., Ph.D., to its scientific advisory board.
Arthur A. Levin, Ph.D., joined MiRagen Therapeutics as evp, R&D. Dr. Levin has worked in the pharmaceutical and biotech industries for over 30 years in many positions, including CDO of Santaris Pharma. He led the project that brought the first microRNA inhibitor into human clinical trials.
IntegraGen named Michael E. Dresner national sales director…Iroko Pharmaceuticals appointed Clarence L. Young, M.D., as CMO and Moji James as general counsel and vp. AcelRx Pharmaceuticals hired Kimberley Gaumer as vp, regulatory affairs and quality assurance…Theorem Clinical Research named Patricia Bland executive director of corporate development.
Gerald McMahon, Ph.D., is now president and CEO of Kolltan Pharmaceuticals. Dr. McMahon previously worked at MedImmune, the biologics arm of AstraZeneca, as svp, R&D oncology. Before that, he was venture partner at Bay City Capital.
Albany Molecular Research hired Saravanakumar Dhakshinamoorthy, Ph.D., as director of in vitro biology and promoted Christopher Conway to vp, business development, North America, and Louis Garguilo to vp, business development…International Stem Cell promoted Simon Craw, Ph.D., to evp with responsibility for business development and investor relations.
Array BioPharma named Ron Squarer CEO; he has also been named to the board of directors. Squarer served as CCO of Hospira and svp, global corporate and business development at Mayne Pharma. He has also held senior management roles at Pfizer and SmithKline Beecham Pharmaceuticals.
Cynapsus Therapeutics appointed Abraham Lieberman, M.D., to its clinical advisory board…Stephanie Leouzon joined the board of Immunovaccine…Zyngenia appointed David Parkinson, M.D., as a member of its board of directors, head of its clinical advisory board, and interim CMO.
Send your People Announcements to firstname.lastname@example.org.